Lucien M. Levy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lucien M. Levy has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Joseph Degnan
Department of Radiology (A.J.D.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
9 shared publications A.T. Rao
From the George Washington University Medical Center (A.T.R., L.M.L.), Washington, DC
1 shared publicationG. Suffredini
From the George Washington University School of Medicine and Health Sciences (G.S.), Washington, DC
1 shared publicationI. Velicu
1 shared publicationIgor Levy-Reis
1 shared publicationJ. H. Weh
1 shared publication
Latest Publications
- Open Access
- 26 December 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (9) , 1681-1682
Genetics of Ataxias: Hereditary Forms
SCA : spinocerebellar ataxia Ataxia is a neurologic disorder in which there is loss of coordination of movement. It can result from dysfunction of the cerebellum and brain stem and their afferent or efferent pathways. The etiology of ataxia can be divided into 3 main categories: acquired,
- 26 December 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (9) , 1681-1682
Open AccessGenetics of Ataxias: Hereditary Forms
SCA : spinocerebellar ataxia Ataxia is a neurologic disorder in which there is loss of coordination of movement. It can result from dysfunction of the cerebellum and brain stem and their afferent or efferent pathways. The etiology of ataxia can be divided into 3 main categories: acquired,
- Open Access
- 15 November 2013
- Published by MDPI AG in Brain Sciences
- Vol. 3 (4) , 1483-1553
Olfactory Hallucinations without Clinical Motor Activity: A Comparison of Unirhinal with Birhinal Phantosmia
Olfactory hallucinations without subsequent myoclonic activity have not been well characterized or understood. Herein we describe, in a retrospective study, two major forms of olfactory hallucinations labeled phantosmias: one, unirhinal, the other, birhinal. To describe these disorders we performed several procedures to elucidate similarities and differences between these processes. From 1272, patients evaluated for taste and smell dysfunction at The Taste and Smell Clinic, Washington, DC with clinical history, neurological and otolaryngological examinations, evaluations of taste and smell function, EEG and neuroradiological studies 40 exhibited cyclic unirhinal phantosmia (CUP) usually without hyposmia whereas 88 exhibited non-cyclic birhinal phantosmia with associated symptomology (BPAS) with hyposmia. Patients with CUP developed phantosmia spontaneously or after laughing, coughing or shouting initially with spontaneous inhibition and subsequently with Valsalva maneuvers, sleep or nasal water inhalation; they had frequent EEG changes usually ipsilateral sharp waves. Patients with BPAS developed phantosmia secondary to several clinical events usually after hyposmia onset with few EEG changes; their phantosmia could not be initiated or inhibited by any physiological maneuver. CUP is uncommonly encountered and represents a newly defined clinical syndrome. BPAS is commonly encountered, has been observed previously but has not been clearly defined. Mechanisms responsible for phantosmia in each group were related to decreased gamma-aminobutyric acid (GABA) activity in specific brain regions. Treatment which activated brain GABA inhibited phantosmia in both groups.
- 15 November 2013
- Published by MDPI AG in Brain Sciences
- Vol. 3 (4) , 1483-1553
Open AccessOlfactory Hallucinations without Clinical Motor Activity: A Comparison of Unirhinal with Birhinal Phantosmia
Olfactory hallucinations without subsequent myoclonic activity have not been well characterized or understood. Herein we describe, in a retrospective study, two major forms of olfactory hallucinations labeled phantosmias: one, unirhinal, the other, birhinal. To describe these disorders we performed several procedures to elucidate similarities and differences between these processes. From 1272, patients evaluated for taste and smell dysfunction at The Taste and Smell Clinic, Washington, DC with clinical history, neurological and otolaryngological examinations, evaluations of taste and smell function, EEG and neuroradiological studies 40 exhibited cyclic unirhinal phantosmia (CUP) usually without hyposmia whereas 88 exhibited non-cyclic birhinal phantosmia with associated symptomology (BPAS) with hyposmia. Patients with CUP developed phantosmia spontaneously or after laughing, coughing or shouting initially with spontaneous inhibition and subsequently with Valsalva maneuvers, sleep or nasal water inhalation; they had frequent EEG changes usually ipsilateral sharp waves. Patients with BPAS developed phantosmia secondary to several clinical events usually after hyposmia onset with few EEG changes; their phantosmia could not be initiated or inhibited by any physiological maneuver. CUP is uncommonly encountered and represents a newly defined clinical syndrome. BPAS is commonly encountered, has been observed previously but has not been clearly defined. Mechanisms responsible for phantosmia in each group were related to decreased gamma-aminobutyric acid (GABA) activity in specific brain regions. Treatment which activated brain GABA inhibited phantosmia in both groups.
- Open Access
- 14 November 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (6) , 1070-1072
Genetics of Huntington Disease
- 14 November 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (6) , 1070-1072
Open AccessGenetics of Huntington Disease
- Open Access
- 18 April 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 34 (12) , 2250-2251
Neurofibromatosis: Types 1 and 2
SUMMARY: Neurofibromatosis types 1 and 2 are a group of neurocutaneous syndromes resulting from disorders in cell regulation. Despite sharing a common name, neurofibromatosis types 1 and 2 are quite distinct phakomatoses, both clinically and genetically.
- 18 April 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 34 (12) , 2250-2251
Open AccessNeurofibromatosis: Types 1 and 2
SUMMARY: Neurofibromatosis types 1 and 2 are a group of neurocutaneous syndromes resulting from disorders in cell regulation. Despite sharing a common name, neurofibromatosis types 1 and 2 are quite distinct phakomatoses, both clinically and genetically.
- Open Access
- 4 April 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 34 (9) , 1690-1691
Inherited Forms of Creutzfeldt-Jakob Disease
- 4 April 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 34 (9) , 1690-1691
Open AccessInherited Forms of Creutzfeldt-Jakob Disease
- Open Access
- 28 March 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (7) , 1246-1253
New Applications of Nanotechnology for Neuroimaging
SUMMARY: Advances in nanotechnology have the potential to dramatically enhance the detection of neurologic diseases with targeted contrast agents and to facilitate the delivery of focused therapies to the central nervous system. We present the physicochemical rationale for their use, applications in animal models, and ongoing clinical trials using these approaches. We highlight advances in the use of nanoparticles applied to brain tumor imaging, tumor angiogenesis, neurodegeneration, grafted stem cells, and neuroprogenitor cells.
- 28 March 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (7) , 1246-1253
Open AccessNew Applications of Nanotechnology for Neuroimaging
SUMMARY: Advances in nanotechnology have the potential to dramatically enhance the detection of neurologic diseases with targeted contrast agents and to facilitate the delivery of focused therapies to the central nervous system. We present the physicochemical rationale for their use, applications in animal models, and ongoing clinical trials using these approaches. We highlight advances in the use of nanoparticles applied to brain tumor imaging, tumor angiogenesis, neurodegeneration, grafted stem cells, and neuroprogenitor cells.
- Open Access
- 28 March 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 34 (5) , 942-943
Brain Mapping Project: Clinical Aspects and Role of Neuroradiology
SUMMARY: As experts in the realm of applying brain imaging technology for meaningful information on an individual patient's medical care, neuroradiologists can provide a physiologic, pathophysiologic, and clinical context for the advances achieved from brain-mapping. Precise identification of the abnormalities involved in brain conditions resulting from a multidisciplinary effort including neuroradiology will help to further define the nature of the pathology, evaluate the results of therapy, and improve health care.
- 28 March 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 34 (5) , 942-943
Open AccessBrain Mapping Project: Clinical Aspects and Role of Neuroradiology
SUMMARY: As experts in the realm of applying brain imaging technology for meaningful information on an individual patient's medical care, neuroradiologists can provide a physiologic, pathophysiologic, and clinical context for the advances achieved from brain-mapping. Precise identification of the abnormalities involved in brain conditions resulting from a multidisciplinary effort including neuroradiology will help to further define the nature of the pathology, evaluate the results of therapy, and improve health care.
- Open Access
- 13 March 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (3) , 457-458
Genetics of Alzheimer Disease
SUMMARY: Alzheimer disease prevails as a major cause of disability in the elderly population and ranks as the most common form of dementia that affects 1 of 8 individuals older than 65 years of age. Most AD cases are late in onset and are probably influenced by both genetic and environmental factors. Apart from age, the risk factors include family history; brain injury, both traumatic and vascular; and metabolic diseases, such as diabetes, hypercholesterolemia, and obesity. Based on twin studies, inheritance plays a role in approximately 80% of cases (familial and sporadic).
- 13 March 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (3) , 457-458
Open AccessGenetics of Alzheimer Disease
SUMMARY: Alzheimer disease prevails as a major cause of disability in the elderly population and ranks as the most common form of dementia that affects 1 of 8 individuals older than 65 years of age. Most AD cases are late in onset and are probably influenced by both genetic and environmental factors. Apart from age, the risk factors include family history; brain injury, both traumatic and vascular; and metabolic diseases, such as diabetes, hypercholesterolemia, and obesity. Based on twin studies, inheritance plays a role in approximately 80% of cases (familial and sporadic).
- Open Access
- 22 February 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (3) , 418-423
Neuroimaging of Rapidly Progressive Dementias, Part 1: Neurodegenerative Etiologies
SUMMARY: Most dementias begin insidiously, developing slowly and generally occurring in the elderly age group. The so-called rapidly progressive dementias constitute a different, diverse collection of conditions, many of which are reversible or treatable. For this reason, prompt identification and assessment of acute and subacute forms of dementia are critical to effective treatment. Numerous other entities within this category of presenile rapid-onset dementias are untreatable such as the prion-related diseases. Neuroimaging aids in the diagnosis and evaluation of many of these rapidly progressive dementias, which include myriad conditions ranging from variations of more common neurodegenerative dementias, such as Alzheimer disease, dementia with Lewy bodies, and frontotemporal dementia; infectious-related dementias such as acquired immune deficiency syndrome dementia; autoimmune and malignancy-related conditions; to toxic and metabolic forms of encephalopathy. This first of a 2-part review will specifically address the ability of MR imaging and ancillary neuroimaging strategies to support the diagnostic evaluation of rapidly progressive dementias due to neurodegenerative causes.
- 22 February 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (3) , 418-423
Open AccessNeuroimaging of Rapidly Progressive Dementias, Part 1: Neurodegenerative Etiologies
SUMMARY: Most dementias begin insidiously, developing slowly and generally occurring in the elderly age group. The so-called rapidly progressive dementias constitute a different, diverse collection of conditions, many of which are reversible or treatable. For this reason, prompt identification and assessment of acute and subacute forms of dementia are critical to effective treatment. Numerous other entities within this category of presenile rapid-onset dementias are untreatable such as the prion-related diseases. Neuroimaging aids in the diagnosis and evaluation of many of these rapidly progressive dementias, which include myriad conditions ranging from variations of more common neurodegenerative dementias, such as Alzheimer disease, dementia with Lewy bodies, and frontotemporal dementia; infectious-related dementias such as acquired immune deficiency syndrome dementia; autoimmune and malignancy-related conditions; to toxic and metabolic forms of encephalopathy. This first of a 2-part review will specifically address the ability of MR imaging and ancillary neuroimaging strategies to support the diagnostic evaluation of rapidly progressive dementias due to neurodegenerative causes.
- Open Access
- 14 February 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (3) , 424-431
Neuroimaging of Rapidly Progressive Dementias, Part 2: Prion, Inflammatory, Neoplastic, and Other Etiologies
SUMMARY: Most dementias begin insidiously, developing slowly and generally occurring in the elderly age group. The so-called rapidly progressive dementias constitute a different, diverse collection of conditions, many of which are reversible or treatable. For this reason, accurate identification and assessment of acute and subacute forms of dementia are critical to effective treatment; neuroimaging aids greatly in narrowing the diagnosis of these conditions. This second installment of a 2-part review of rapidly progressive dementias examines the use of imaging in an assortment of other etiologies in the differential diagnosis, from prion disease and neoplastic-related conditions to rare metabolic and other conditions such as Wernicke encephalopathy. In these clinical conditions, MR imaging has the potential to narrow this broad differential diagnosis and, at times, can definitively aid in the diagnosis of certain conditions on the basis of typical imaging patterns.
- 14 February 2013
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (3) , 424-431
Open AccessNeuroimaging of Rapidly Progressive Dementias, Part 2: Prion, Inflammatory, Neoplastic, and Other Etiologies
SUMMARY: Most dementias begin insidiously, developing slowly and generally occurring in the elderly age group. The so-called rapidly progressive dementias constitute a different, diverse collection of conditions, many of which are reversible or treatable. For this reason, accurate identification and assessment of acute and subacute forms of dementia are critical to effective treatment; neuroimaging aids greatly in narrowing the diagnosis of these conditions. This second installment of a 2-part review of rapidly progressive dementias examines the use of imaging in an assortment of other etiologies in the differential diagnosis, from prion disease and neoplastic-related conditions to rare metabolic and other conditions such as Wernicke encephalopathy. In these clinical conditions, MR imaging has the potential to narrow this broad differential diagnosis and, at times, can definitively aid in the diagnosis of certain conditions on the basis of typical imaging patterns.